CA3221494A1 - Cancer detection method, kit, and system - Google Patents
Cancer detection method, kit, and system Download PDFInfo
- Publication number
- CA3221494A1 CA3221494A1 CA3221494A CA3221494A CA3221494A1 CA 3221494 A1 CA3221494 A1 CA 3221494A1 CA 3221494 A CA3221494 A CA 3221494A CA 3221494 A CA3221494 A CA 3221494A CA 3221494 A1 CA3221494 A1 CA 3221494A1
- Authority
- CA
- Canada
- Prior art keywords
- mir
- hsa
- cancer
- mirna
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Evolutionary Biology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Organic Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Databases & Information Systems (AREA)
- Immunology (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Software Systems (AREA)
- Hospice & Palliative Care (AREA)
- Evolutionary Computation (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208506P | 2021-06-09 | 2021-06-09 | |
| US63/208,506 | 2021-06-09 | ||
| PCT/US2022/032423 WO2022261039A2 (en) | 2021-06-09 | 2022-06-07 | Cancer detection method, kit, and system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3221494A1 true CA3221494A1 (en) | 2022-12-15 |
Family
ID=84426392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3221494A Pending CA3221494A1 (en) | 2021-06-09 | 2022-06-07 | Cancer detection method, kit, and system |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4352266A4 (de) |
| JP (1) | JP2024523848A (de) |
| CN (1) | CN117500941A (de) |
| AU (1) | AU2022289858A1 (de) |
| CA (1) | CA3221494A1 (de) |
| WO (1) | WO2022261039A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110799648B (zh) * | 2017-06-29 | 2024-03-22 | 东丽株式会社 | 用于检测肺癌的试剂盒、装置和方法 |
| CA3098105A1 (en) * | 2018-04-25 | 2019-10-31 | Toray Industries, Inc. | Kit, device, and method for detecting bladder cancer |
| CN117802235B (zh) * | 2022-09-30 | 2025-08-19 | 上海思路迪生物医学科技有限公司 | 血液胞外囊泡miRNA在卵巢癌诊断中的应用 |
| KR20250159710A (ko) * | 2023-03-13 | 2025-11-11 | 미론콜 다이아그노스틱스 리미티드 | 암 진단 모델의 개발 방법 및 암 검출 방법 개발에서의 이의 용도 |
| WO2025128926A1 (en) * | 2023-12-13 | 2025-06-19 | Amazon Technologies, Inc. | Methods of identifying and treating individuals with elevated cancer risk |
| WO2026015599A1 (en) * | 2024-07-10 | 2026-01-15 | Mironcol Diagnostics, Ltd. | Machine learning-based diagnostic classifiers for predicting cancer tissue of origin |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9495515B1 (en) * | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US20120041274A1 (en) * | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| US20150011414A1 (en) * | 2012-01-16 | 2015-01-08 | Herlev Hospital | Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples |
| US9708667B2 (en) * | 2014-05-13 | 2017-07-18 | Rosetta Genomics, Ltd. | MiRNA expression signature in the classification of thyroid tumors |
| EP3191602A1 (de) * | 2014-09-09 | 2017-07-19 | Istituto Europeo di Oncologia S.r.l. | Verfahren zur erkennung von lungenkrebs |
| JP7165329B2 (ja) * | 2017-04-28 | 2022-11-04 | 東レ株式会社 | 卵巣腫瘍の検出のためのキット、デバイス及び方法 |
| US20220359037A1 (en) * | 2018-03-23 | 2022-11-10 | The Regents Of The University Of California | Non-Invasive Classification of Benign and Malignant Melanocytic Lesions Using MicroRNA Profiling |
| JP2020188683A (ja) * | 2019-05-17 | 2020-11-26 | 株式会社Aldock | 胃癌または食道癌を検出するための癌マーカー |
-
2022
- 2022-06-07 EP EP22820856.7A patent/EP4352266A4/de active Pending
- 2022-06-07 CA CA3221494A patent/CA3221494A1/en active Pending
- 2022-06-07 CN CN202280041034.8A patent/CN117500941A/zh active Pending
- 2022-06-07 JP JP2023576034A patent/JP2024523848A/ja active Pending
- 2022-06-07 WO PCT/US2022/032423 patent/WO2022261039A2/en not_active Ceased
- 2022-06-07 AU AU2022289858A patent/AU2022289858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024523848A (ja) | 2024-07-02 |
| WO2022261039A3 (en) | 2023-01-19 |
| EP4352266A4 (de) | 2025-12-10 |
| EP4352266A2 (de) | 2024-04-17 |
| WO2022261039A2 (en) | 2022-12-15 |
| AU2022289858A1 (en) | 2024-01-04 |
| CN117500941A (zh) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3221494A1 (en) | Cancer detection method, kit, and system | |
| JP5415963B2 (ja) | 新しい癌マーカー | |
| US11198909B2 (en) | Risk scores based on human phosphodiesterase 4D variant 7 expression | |
| JP2014509189A (ja) | 結腸ガン遺伝子発現シグネチャーおよび使用方法 | |
| JP2009508493A (ja) | すい臓がんを診断するための方法 | |
| EP3548631B1 (de) | Risikobewertungen auf basis der expression der variante 7 von humaner phosphodiesterase 4d | |
| AU2026202126A1 (en) | Biomarkers for renal cell carcinoma | |
| US20250137066A1 (en) | Compostions and methods for diagnosing lung cancers using gene expression profiles | |
| JP6611411B2 (ja) | 膵臓がんの検出キット及び検出方法 | |
| US20170283877A1 (en) | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease | |
| JP2024519082A (ja) | 肝細胞がんのdnaメチル化バイオマーカー | |
| JP6383541B2 (ja) | 胆管がんの検出キット及び検出方法 | |
| CN111315897B (zh) | 用于黑素瘤检测的方法 | |
| US20240209451A1 (en) | Cancer detection method, kit, and system | |
| CN110387423A (zh) | 前庭神经鞘瘤诊断用生物标志物 | |
| Bender et al. | LASSO logistic regression reveals a mixed MiRNA and serum-marker classifier for prediction of immunotherapy response in liquid biopsies of melanoma patients | |
| CN114746551A (zh) | 大肠癌诊断用标志物、辅助大肠癌的诊断的方法、收集数据以用于大肠癌诊断的方法、大肠癌的诊断试剂盒、大肠癌治疗药物、大肠癌的治疗方法、大肠癌的诊断方法 | |
| KR20250159710A (ko) | 암 진단 모델의 개발 방법 및 암 검출 방법 개발에서의 이의 용도 | |
| US20260035748A1 (en) | Methods for detecting and treating idiopathic pulmonary fibrosis | |
| HK40126608A (zh) | 开发癌症诊断模型的方法及其在开发癌症检测方法中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250602 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250602 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20260201 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20260201 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260201 |